CX
C21 Investments Inc.
CXXIF · OTC
$0.26 -0.11% (-$0.00)
1M +8.47%
Market Cap $31.4M
P/E Ratio -
Div. Yield -
ROE 16.95%
Bulios Fair Price
$0.17
35.8% downside
Current Price
$0.26
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CXXIF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
71 /100
Cheap EV/EBITDA 12.95x
P/FCF 22.24x
P/S 1.00x
Growth
28 /100
Declining Rev. growth 8.50%
Book val. growth 36.21%
FCF growth 2.96%
Profitability
28 /100
Weak Gross margin 35.63%
FCF margin 4.48%
Net margin 13.91%
Quality
7 /100
Poor ROIC 85.44%
Asset turnover 0.59x
ROE 16.95%
Debt
55 /100
Moderate Debt/Equity 0.42x
Net debt/EBITDA 2.47x
Current ratio 1.24x
Stability
31 /100
Unstable Beta 1.88x
Profitable years 0
Rev. volatility 6.02%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CXXIF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Sonny Newman
Employees
114
Headquarters
Vancouver
Upcoming events
10 NOV
Earnings
Upcoming earnings report